Saroja Pharma Industries India Limited

Saroja Pharma Industries India Limited - chemicals and materials in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN U24110MH2019PLC319508 Incorporated 14 January 2019 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: SAROJA Public Limited Company chemicals and materials Startup India MSME · Small
Market Cap
₹14.51 Cr
SAROJA-SM · NSE
Share Price
₹34.30
-4.99% today
Revenue
₹70.13 Cr
FY 2025-26 · +30.5% YoY
EBITDA
₹3.73 Cr
Margin 5.3%
Net Profit
₹1.68 Cr
FY 2025-26 · +61.5% YoY
P/E (TTM)
9.1x
P/B 0.9x
ROE
9.8%
ROCE 13.1%
Debt / Equity
0.72
Interest cover 41.2x

About Saroja Pharma Industries India Limited

Data last updated:

Saroja Pharma Industries India Limited is a public limited company based in Mumbai, Maharashtra, India, recognised as a startup by DPIIT. It operates in the chemical distribution and retail segment of the chemicals and materials sector. It was incorporated on 14 January 2019 and has been in existence for over 7 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24110MH2019PLC319508. Its GSTIN is 27ABBCS4207N1Z5 (Maharashtra). It is a listed company as per MCA records. Its shares are listed on NSE: SAROJA.

The company has an authorised share capital of ₹5 Cr and a paid-up capital of ₹4.02 Cr. It is led by directors including Biju Gopinathan Nair (Managing Director) and Manish Dasharath Kamble (Whole-Time Director).

Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 305 Kailash Tower Shiv Shristi Complex Goregaon Link Road Mulund West, Mumbai, Maharashtra, India – 400080.

As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹70.13 Cr, a growth of 30.5% compared to the previous year. For the same year it recorded a net profit of ₹1.68 Cr (net margin 2.4%) and EBITDA of ₹3.73 Cr (EBITDA margin 5.3%). The net worth stands at ₹17.29 Cr (up 10.3% YoY). Total assets are valued at ₹31.7 Cr (up 26.1% YoY).

The company is associated with 1 brand: Saroja Pharma. As per MCA filings, the company has open charges of ₹9.48 Cr and satisfied charges of ₹6.55 Cr on record. The company has 3 deals on record (2 funding rounds, 1 ipo), with disclosed funding of ₹1.95 Cr; the latest was in September 2023. Its 5 peer companies in the Chemicals industry (Chemical Retail and Distribution), with the same principal business activity (wholesale trading) are compared by revenue, 3 larger and 2 smaller; the largest is VPB Infratech Private Limited with revenue of ₹54.03 Cr.

Saroja Pharma Industries India Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-19-0061715). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sarojapharma.com.

Company details

CIN U24110MH2019PLC319508
Registration Number 319508
Incorporation Date 14 January 2019
ROC Mumbai
Listing Status Listed (NSE: SAROJA)
Company Status Active
Compliance Status Active Compliant
DPIIT Recognition Recognised Startup
MSME Classification Small
Udyam Registration UDYAM-MH-19-0061715

CIN history

Saroja Pharma Industries India has one previous CIN (Corporate Identification Number): U24110MH2019PTC319508. The current CIN is U24110MH2019PLC319508, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
U24110MH2019PLC319508Current
U24110MH2019PTC319508Previous

Recognitions & Rankings of Saroja Pharma Industries India

Startup India Government of India
MSME (Udyam registered) Ministry of MSME
Category
Small (2024-25)
Udyam number
UDYAM-MH-19-0061715

Contact details

Saroja Pharma Industries India Limited's registered office is in Mumbai, Maharashtra. Its website is sarojapharma.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Registered Address
    305 Kailash Tower Shiv Shristi Complex Goregaon Link Road Mulund West, Mumbai, Maharashtra, India – 400080
  • Industry
    Chemicals and Materials, Chemical Distribution & Retail

To see the full contact details of Saroja Pharma Industries India Limited, buy the company report.

Comprehensive company report
Saroja Pharma Industries India Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Saroja Pharma Industries India operates one associated brand: Saroja Pharma. Each brand links to its own profile.

BrandDescriptionWebsite
Specialty chemical trader, exporter, and supplier that offers a range of products, with a focus on pharmaceutical ingredientssarojapharma.com

Business activity

The main business activity of Saroja Pharma Industries India is trade. In detail, this covers wholesale trading.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
GTradeG1Wholesale Trading

To see the full business activity and turnover split of Saroja Pharma Industries India Limited, buy the company report.

Financials of Saroja Pharma Industries India Limited

FY 2025-26 filings available

Saroja Pharma Industries India Limited reported revenue of ₹70.13 Cr (up 30.5% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹70.13 Cr
+30.5% YoY
EBITDA
₹3.73 Cr
+33.7% YoY
Profit After Tax
₹1.68 Cr
+61.5% YoY
Net Worth
₹17.29 Cr
+10.3% YoY
Total Assets
₹31.70 Cr
+26.1% YoY
Total Debt
₹14.41 Cr
+52.3% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue70.1353.7340.6750.1955.6336.66
Revenue growth+30.5%+32.1%-19.0%-9.8%+51.8%-
EBITDA3.732.792.572.722.091.31
EBITDA margin+5.3%+5.2%+6.3%+5.4%+3.8%+3.6%
Profit before tax2.241.461.221.491.561.05
Net profit1.681.040.891.061.120.75
Net profit margin+2.4%+1.9%+2.2%+2.1%+2.0%+2.1%
EPS (₹)4.022.572.183.6150.49731.30
Balance sheet
Total assets31.7025.1320.3815.2810.163.95
Net worth17.2915.6814.645.094.030.94
Total debt14.419.465.7310.186.143.02
Cash & bank0.340.330.320.360.260.00
Net working capital8.5112.8111.4310.109.753.83
Cash flow
Cash from operations7.441.151.022.19(3.67)(1.05)
Cash from investing(11.68)(2.70)(4.76)(4.82)(0.34)(0.05)
Cash from financing4.251.563.702.734.271.03

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 18 Nov 2026
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue70.1353.7340.6750.1955.6336.66
Revenue growth+30.5%+32.1%-19.0%-9.8%+51.8%-
Other income0.110.190.190.160.320.09
Total expenses66.4050.9438.1047.4753.5435.35
Employee cost0.690.740.920.830.730.55
EBITDA3.732.792.572.722.091.31
EBITDA margin+5.3%+5.2%+6.3%+5.4%+3.8%+3.6%
Depreciation0.110.110.090.070.050.02
Interest1.491.411.451.320.800.33
Profit before tax2.241.461.221.491.561.05
Tax0.620.420.330.430.440.30
Net profit1.681.040.891.061.120.75
Net profit margin+2.4%+1.9%+2.2%+2.1%+2.0%+2.1%
EPS (₹)4.022.572.183.6150.49731.30
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital4.024.024.022.940.230.01
Reserves & surplus13.2711.6610.622.153.800.93
Shareholders' funds (net worth)17.2915.6814.645.094.030.94
Secured loans6.108.483.798.005.131.60
Unsecured loans8.310.981.942.181.011.42
Total debt14.419.465.7310.186.143.02
Total liabilities31.7025.1320.3815.2810.163.95
Assets
Gross block2.902.842.742.360.420.12
Net block2.182.502.512.220.350.09
Capital work in progress20.348.616.131.790.000.00
Investments0.540.340.200.140.040.00
Inventories0.860.100.403.870.470.66
Sundry debtors17.3026.5816.2411.1113.987.22
Cash & bank balances0.340.330.320.360.260.00
Loans & advances0.060.210.640.810.380.22
Total current assets18.5627.2217.6016.1515.098.10
Total current liabilities10.0514.416.176.055.344.27
Net working capital8.5112.8111.4310.109.753.83
Total assets31.7025.1320.3815.2810.163.95
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash0.330.320.360.260.000.08
Net cash from operating activities7.441.151.022.19(3.67)(1.05)
Net cash from investing activities(11.68)(2.70)(4.76)(4.82)(0.34)(0.05)
Net cash from financing activities4.251.563.702.734.271.03
Net change in cash0.010.01(0.04)0.100.26(0.07)
Closing cash0.340.330.320.360.260.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth+30.5%+32.1%-19.0%-9.8%+51.8%-
EBITDA growth+33.7%+8.6%-5.5%+30.1%+59.5%-
PBT growth+53.4%+19.7%-18.1%-4.5%+48.6%+9997.0%
Net income growth+61.5%+16.9%-16.0%-5.4%+49.3%-
Revenue CAGR (3Y)+11.8%-1.2%+3.5%---
EBITDA CAGR (3Y)+11.1%+10.1%+25.2%---
Profitability & leverage
Net income margin+2.3%+1.9%+2.2%+2.1%+2.0%+2.1%
Return on capital employed+13.1%+12.6%+14.9%+22.1%+33.7%+34.3%
Return on net worth+9.8%+6.8%+8.9%+23.3%+45.9%+77.7%
Debt / equity0.720.500.811.791.843.21
Long-term debt / equity0.270.130.280.490.631.51
Interest cover41.1652.6158.4749.8139.2225.58
Efficiency & per share
Fixed asset turnover24.4419.2615.9536.11206.04305.50
Inventory turnover146.10214.9219.0523.1398.4655.55
Debtors turnover3.202.512.974.005.255.08
EPS (₹)4.022.572.183.6150.49731.30
Dividend per share (₹)0.000.000.000.000.000.00
Book value per share (₹)43.0038.9936.4217.33178.30935.90

To see the full year-wise statements and ratios of Saroja Pharma Industries India Limited, buy the company report.

Board of directors of Saroja Pharma Industries India Limited

Saroja Pharma Industries India has 8 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Anita SethiaDirector03 Sep 20251 Years 2 MonthsCurrent
Pulinattu NandakumarDirector02 Feb 20233 Years 9 MonthsCurrent
Sonal JainDirector09 May 20233 Years 6 MonthsCurrent
Santosh Shivram PalavAdditional Director09 Oct 20251 Years 1 MonthsCurrent
Biju Gopinathan NairManaging Director14 Jan 20197 Years 10 MonthsCurrent
Manish Dasharath KambleWhole-Time Director14 Jan 20197 Years 10 MonthsCurrent
Showing 6 of 8 current directors. View all directors

Peer comparison

Saroja Pharma Industries India Limited is compared with the 5 companies closest to it by revenue in the Chemicals industry (Chemical Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Saroja Pharma Industries India Limitedthis company₹70.13 Cr (FY 2026)₹1.68 Cr2.4%30.5%Mumbai, Maharashtra, India
VPB Infratech Private Limited₹54.03 Cr (FY 2025)138.0%Jaipur, Rajasthan, India
Jinendra Enterprise Private Limited₹54.02 Cr (FY 2025)36.0%Ahmedabad, Gujarat, India
Rivercraft Uniglobal Enterprises Private Limited₹53.94 Cr (FY 2025)-6.0%Mumbai, Maharashtra, India
S.N. Dyechem Private Limited₹53.65 Cr (FY 2024)113.0%New Delhi, Delhi, India
Roop Rasayan Industries Private Limited₹53.61 Cr (FY 2025)-34.0%Mumbai, Maharashtra, India

To see the full peer comparison of Saroja Pharma Industries India Limited, buy the company report.

Auditor

Saroja Pharma Industries India Limited is audited by Pravin Chandak & Associates for the financial year 2023.

Auditor firmFinancial yearFirm registration number
Pravin Chandak & AssociatesFY 2023116627W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 73.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 27.00%.

Promoters: 73.00%Retail & Others: 27.00%
Sep 2026
QUARTER
73.00% Promoters
27.00% Retail & Others
Promoter holding - history
Now 73.00% · Sep 2026High 73.00% · Dec 2025Low 73.00% · Dec 2025
72%72.5%73%73.5%74%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 73.00%Mar 2026: 73.00%Jun 2026: 73.00%Sep 2026: 73.00%73.00%73.00%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters73.00%73.00%73.00%73.00%
Public27.00%27.00%27.00%27.00%

Charges & borrowings

Open charges
₹9.48 Cr
Satisfied charges
₹6.55 Cr
Breakdown by lending institutions
Others₹9.48 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
21 Sep 2023100793470Others₹28 LakhOpen
14 Jun 2022100582764Others₹8.5 CrOpen
14 Jun 2022100582766Others₹50 LakhOpen
27 Jan 2022100538166Others₹20 LakhOpen
23 Jun 2020100346613Others₹6.5 CrSatisfied

To see the full charge records of Saroja Pharma Industries India Limited, buy the company report.

Total charge records: 6 View all charges

Deals & funding

Saroja Pharma Industries India Limited has 3 deals on record (2 funding rounds, 1 ipo), with disclosed funding of ₹1.95 Cr; the latest was in September 2023.

Total deals
3
Funding rounds
2
IPO
1
Disclosed funding
₹1.95 Cr

Deals on record (3 of 3)

WhenDealAmountParties
Sep 2023IPO₹9.11 CrInvestors: Public Market Investors
Feb 2022Funding round₹1.75 CrInvestors: an individual
Jun 2021Funding round₹20 LakhInvestors: an individual

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Saroja Pharma Industries India Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

GST

Saroja Pharma Industries India has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
27ABBCS4207N1Z5MaharashtraActive21 Jan 2019

To see the full GST registrations and return filing status of Saroja Pharma Industries India Limited, buy the company report.

Recent activity

Saroja Pharma Industries India Limited has 16 board changes on record since 2019: 8 appointments and 8 cessations. The latest: Ravindra Shivaji Salaskar was appointed as Whole-Time Director on 09 Oct 2025.

Filing
Saroja Pharma Industries India Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai.
Appointed
Ravindra Shivaji Salaskar was appointed as Whole-Time Director.
Appointed
Santosh Shivram Palav was appointed as Additional Director.
AGM
Saroja Pharma Industries India Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Ceased
Anita Sethia ceased to be Additional Director.
Appointed
Anita Sethia was appointed as Director.
Ceased
Yogita Maheshwari ceased to be CFO.
Charges
A charge with Others of Rs. 8.50 Cr registered on 14 Jun 2022 with Charge ID 100582764 was modified on 02 Apr 2024.
Charges
A charge with Others amounted to Rs. 0.28 Cr with Charge ID 100793470 was registered on 21 Sep 2023.
Ceased
Sonal Jain ceased to be Additional Director.
Appointed
Sonal Jain was appointed as Director.
Ceased
Abhishek Agrawal ceased to be Additional Director.

17 earlier events are in the company report.

Frequently asked questions

Saroja Pharma Industries India is an active public limited company based in Mumbai, Maharashtra, India. The company works in chemical distribution and retail, within the chemicals and materials industry. It was incorporated on 14 January 2019 (7+ years old) and is registered under CIN U24110MH2019PLC319508. Listed on NSE: SAROJA.

Saroja Pharma Industries India reported revenue of ₹70.13 Cr for FY 2025-26 (up 30.5% YoY) based on standalone financials.

Saroja Pharma Industries India has 8 current directors:

The latest financial statements of Saroja Pharma Industries India on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2019 are in the company report.

The GSTIN of Saroja Pharma Industries India is 27ABBCS4207N1Z5, registered in Maharashtra.

The CIN (Corporate Identification Number) of Saroja Pharma Industries India is U24110MH2019PLC319508. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Saroja Pharma Industries India is a listed company as per MCA records. Its shares are listed on NSE (symbol: SAROJA).

Saroja Pharma Industries India was incorporated on 14 January 2019, making it 7+ years old. It is registered with the Registrar of Companies, Mumbai.

Saroja Pharma Industries India has 3 deals on record (2 funding rounds, 1 ipo), with disclosed funding of ₹1.95 Cr; the latest was in September 2023.

The peers of Saroja Pharma Industries India by revenue are VPB Infratech Private Limited, Jinendra Enterprise Private Limited, Rivercraft Uniglobal Enterprises Private Limited, S.N. Dyechem Private Limited, Roop Rasayan Industries Private Limited, all in the Chemicals industry (Chemical Retail and Distribution), with the same principal business activity (wholesale trading).

Ravindra Shivaji Salaskar was appointed as Whole-Time Director on 09 Oct 2025. Santosh Shivram Palav was appointed as Additional Director on 09 Oct 2025. Anita Sethia ceased to be Additional Director on 29 Sep 2025. Saroja Pharma Industries India has 16 board changes on record in total.